Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DYRK1A | Q13627 | 20/20 | 0.41 |
| ▸ | GSK3B | P49841 | 13/20 | 0.41 |
| ▸ | CLK2 | P49760 | 3/20 | 0.38 |
| ▸ | CLK3 | P49761 | 3/20 | 0.38 |
| ▸ | WNT1 | P04628 | 3/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5038892 | 0.89 | DYRK1A (0.41) | DYRK1AGSK3BCLK2CLK3WNT1 | |
| SCHEMBL1175540 | 0.89 | DYRK1A (0.41) | DYRK1AGSK3BCLK2CLK3WNT1 | |
| Formic Acid SCHEMBL5562289 | 0.85 | DYRK1A (0.39) | DYRK1AGSK3BCLK2CLK3WNT1 | |
| SCHEMBL1176152 | 0.82 | JAK2 (0.38) | DYRK1AGSK3BCLK2CLK3 | |
| SCHEMBL5039448 | 0.82 | JAK2 (0.38) | DYRK1AGSK3BCLK2CLK3 | |
| SCHEMBL4261851 | 0.80 | DYRK1A (0.43) | DYRK1AGSK3BCLK2CLK3WNT1 | |
| Formic Acid SCHEMBL5563840 | 0.79 | JAK2 (0.36) | DYRK1AGSK3BCLK2CLK3 | |
| SCHEMBL2013744 | 0.78 | KDM4E (0.46) | — | |
| SCHEMBL1176398 | 0.77 | DYRK1A (0.48) | DYRK1AGSK3BCLK2CLK3WNT1 | |
| SCHEMBL5043123 | 0.77 | DYRK1A (0.48) | DYRK1AGSK3BCLK2CLK3WNT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7964600-B2 | Indoles, 1H-indazoles, 1,2-benzisoxazoles, and 1,2-benzisothiazoles, and preparation and uses thereof | MEMORY PHARMACEUTICALS CORPORATION (US) | 2011-06-21 | — | — | US | disclosed |
| US-20110028483-A1 | INDOLES, 1H-INDAZOLES, 1,2-BENZISOXAZOLES, AND 1,2-BENZISOTHIAZOLES, AND PREPARATION AND USES THEREOF | XIE WENGE | 2011-02-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110028483-A1 | INDOLES, 1H-INDAZOLES, 1,2-BENZISOXAZOLES, AND 1,2-BENZISOTHIAZOLES, AND PREPARATION AND USES THEREOF | CHRNA7, CHRNA5, CHRNA1 | DYRK1A 1504/4885GSK3B 608/4885CLK2 1801/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.